3 Resilient Dividend Stocks to Consider During a Stock Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Source: NASDAQ.COM
AbbVie and Its Resilience: AbbVie is highlighted as a strong investment due to its robust pipeline and consistent dividend payments, making it likely to withstand market downturns better than many other stocks.
Enterprise Products Partners' Stability: This midstream energy company is noted for its reliable cash flow and long-term contracts, making it a solid choice for dividend investors, especially with a distribution yield of 6.8%.
Pfizer's Attractive Dividend: Despite facing challenges like a patent cliff, Pfizer offers a high dividend yield of 7.15% and has a promising pipeline of products that could mitigate potential sales declines.
Market Outlook and Investment Strategy: The article warns of potential market corrections due to high valuations and suggests considering the top 10 stocks identified by analysts for better investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 230.010
Low
223.00
Averages
252.00
High
289.00
Current: 230.010
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie’s SKYRIZI Approved by EU for Pediatric Psoriasis Treatment
- EU Approval: AbbVie announced that its drug SKYRIZI (risankizumab) has received approval from the European Commission for treating moderate to severe plaque psoriasis in children aged six and older, marking a significant advancement in pediatric dermatology.
- Dosing Innovation: The introduction of a new 55 mg pre-filled syringe (PFS) supports weight-based dosing specifically for patients weighing less than 40 kg, aiming to enhance treatment personalization and efficacy.
- Clinical Data Support: The approval is backed by clinical data from the Phase 3 OptIMMize-1 study involving 137 pediatric patients, demonstrating a safety profile consistent with adults and no new safety signals, thereby boosting physician confidence in the treatment.
- Social Impact: With nearly 70% of pediatric patients relying solely on topical therapies, the approval of SKYRIZI provides more treatment options for children, aiming to improve their quality of life and reduce risks of school absenteeism and social stigma associated with the disease.
See More
SKYRIZI® Approved for Pediatric Psoriasis Treatment
- New Indication Approval: AbbVie announced that SKYRIZI® (risankizumab) has been approved by the European Commission for the treatment of moderate to severe plaque psoriasis in children and adolescents aged six and older, marking a significant advancement in pediatric dermatology.
- Dosing Innovation: The approval includes a new 55 mg pre-filled syringe designed for patients weighing less than 40 kg, enhancing treatment personalization and efficacy, which is expected to improve the quality of life for pediatric patients.
- Clinical Data Support: This approval is backed by data from the Phase 3 OptIMMize-1 and OptIMMize-2 trials involving 137 pediatric patients, demonstrating a safety profile consistent with that of adults, with no new safety signals observed, thereby boosting physician confidence in the treatment.
- Social Impact: Given that nearly a third of psoriasis patients develop symptoms before age 18, the approval of SKYRIZI not only provides more treatment options for children but also has the potential to reduce school absenteeism and social stigma associated with the disease, highlighting its significant societal value.
See More
AbbVie's Boey Receives Health Canada Approval for Frown Lines
- Product Approval: AbbVie's Allergan Aesthetics announced that Boey has received approval from Health Canada for the temporary improvement of moderate to severe glabellar lines, making it the first rapid-onset, short-duration botulinum neurotoxin serotype E approved for this indication.
- Clinical Trial Data: Boey demonstrated significant effects in two Phase 3 trials, with onset of effect as early as eight hours post-injection and glabellar lines returning to baseline severity within 14 to 21 days, indicating its rapid and effective treatment potential.
- Market Preparation: Allergan Aesthetics plans to begin training healthcare professionals on the use of Boey in the coming months and is preparing for its commercial launch in Canada, reflecting a proactive approach to market entry.
- International Review: In addition to Canada, Boey is under regulatory review in several other countries, indicating its potential for future expansion in global markets and enhancing AbbVie's competitive position in the aesthetics sector.
See More
Allergan Aesthetics Receives Health Canada Approval for Boey®
- Product Innovation: Allergan Aesthetics' Boey® (trenibotulinumtoxinE) has received approval from Health Canada, becoming the first rapid-onset, short-duration botulinum neurotoxin for improving moderate to severe glabellar lines, marking a significant advancement in aesthetic medicine and expected to attract patients seeking non-long-term commitments.
- Clinical Research Support: The approval of Boey® is backed by two randomized, double-blind, placebo-controlled Phase 3 clinical trials involving 947 patients, showing that 60% and 65.7% of subjects achieved significant improvement in wrinkle severity by Day 7, demonstrating its efficacy.
- Market Demand: A survey by Allergan Aesthetics found that 80% of respondents are open to learning about new treatment options, and 79% wish they could temporarily preview treatment outcomes, indicating a growing market demand for short-term neurotoxin solutions that Boey® addresses.
- Future Plans: Allergan Aesthetics plans to begin training healthcare professionals on the use of Boey® in the coming months and is preparing for a commercial launch in multiple other countries, reflecting its strategic intent to expand in the global market.
See More
AbbVie and Enanta Gain EU Approval for Maviret Label Expansion
- Label Expansion Approval: AbbVie and Enanta's jointly developed hepatitis C therapy, Maviret, has received EU approval to be indicated for patients aged 3 and older with acute HCV infection, significantly broadening its market applicability.
- Significant Market Demand: Over 12 million individuals in Europe are infected with the hepatitis C virus, which can lead to severe complications such as cirrhosis and end-stage liver disease if untreated, highlighting the drug's potential and importance in addressing this public health issue.
- Clinical Trial Support: The approval is backed by results from late-stage trials demonstrating the efficacy of an eight-week regimen of Maviret, making it the only antiviral therapy available in the EU for both acute and chronic HCV infections, thereby enhancing its competitive edge.
- Strategic Implications: The label expansion of Maviret not only addresses the treatment needs of acute HCV patients but also lays the groundwork for AbbVie and Enanta's further expansion in the global market, strengthening their leadership position in the liver disease treatment sector.
See More
AbbVie’s MAVIRET Receives European Commission Approval for Hepatitis C Treatment
- Drug Approval: AbbVie's MAVIRET has received approval from the European Commission, becoming the only drug in the EU approved for treating both acute and chronic Hepatitis C, marking a significant expansion in the company's global market presence.
- Clinical Trial Success: In a Phase 3 trial involving 286 Hepatitis C patients, MAVIRET achieved a 96.2% sustained virological response at 12 weeks, demonstrating its efficacy and good safety profile, which enhances physician confidence in prescribing the drug.
- Market Potential: Given that Hepatitis C patients are at a significantly higher risk of developing cirrhosis and liver cancer if undiagnosed, the introduction of MAVIRET provides a new treatment option that addresses the urgent market demand for effective therapies.
- Stock Price Reaction: AbbVie's stock closed up 6.25% at $230.01 on Monday, with pre-market trading showing a further increase of 0.44% to $231.11, reflecting positive market sentiment regarding MAVIRET's approval and potentially boosting the company's future financial performance.
See More
AbbVie’s SKYRIZI Approved by EU for Pediatric Psoriasis Treatment
- EU Approval: AbbVie announced that its drug SKYRIZI (risankizumab) has received approval from the European Commission for treating moderate to severe plaque psoriasis in children aged six and older, marking a significant advancement in pediatric dermatology.
- Dosing Innovation: The introduction of a new 55 mg pre-filled syringe (PFS) supports weight-based dosing specifically for patients weighing less than 40 kg, aiming to enhance treatment personalization and efficacy.
- Clinical Data Support: The approval is backed by clinical data from the Phase 3 OptIMMize-1 study involving 137 pediatric patients, demonstrating a safety profile consistent with adults and no new safety signals, thereby boosting physician confidence in the treatment.
- Social Impact: With nearly 70% of pediatric patients relying solely on topical therapies, the approval of SKYRIZI provides more treatment options for children, aiming to improve their quality of life and reduce risks of school absenteeism and social stigma associated with the disease.
See More
SKYRIZI® Approved for Pediatric Psoriasis Treatment
- New Indication Approval: AbbVie announced that SKYRIZI® (risankizumab) has been approved by the European Commission for the treatment of moderate to severe plaque psoriasis in children and adolescents aged six and older, marking a significant advancement in pediatric dermatology.
- Dosing Innovation: The approval includes a new 55 mg pre-filled syringe designed for patients weighing less than 40 kg, enhancing treatment personalization and efficacy, which is expected to improve the quality of life for pediatric patients.
- Clinical Data Support: This approval is backed by data from the Phase 3 OptIMMize-1 and OptIMMize-2 trials involving 137 pediatric patients, demonstrating a safety profile consistent with that of adults, with no new safety signals observed, thereby boosting physician confidence in the treatment.
- Social Impact: Given that nearly a third of psoriasis patients develop symptoms before age 18, the approval of SKYRIZI not only provides more treatment options for children but also has the potential to reduce school absenteeism and social stigma associated with the disease, highlighting its significant societal value.
See More
AbbVie's Boey Receives Health Canada Approval for Frown Lines
- Product Approval: AbbVie's Allergan Aesthetics announced that Boey has received approval from Health Canada for the temporary improvement of moderate to severe glabellar lines, making it the first rapid-onset, short-duration botulinum neurotoxin serotype E approved for this indication.
- Clinical Trial Data: Boey demonstrated significant effects in two Phase 3 trials, with onset of effect as early as eight hours post-injection and glabellar lines returning to baseline severity within 14 to 21 days, indicating its rapid and effective treatment potential.
- Market Preparation: Allergan Aesthetics plans to begin training healthcare professionals on the use of Boey in the coming months and is preparing for its commercial launch in Canada, reflecting a proactive approach to market entry.
- International Review: In addition to Canada, Boey is under regulatory review in several other countries, indicating its potential for future expansion in global markets and enhancing AbbVie's competitive position in the aesthetics sector.
See More
Allergan Aesthetics Receives Health Canada Approval for Boey®
- Product Innovation: Allergan Aesthetics' Boey® (trenibotulinumtoxinE) has received approval from Health Canada, becoming the first rapid-onset, short-duration botulinum neurotoxin for improving moderate to severe glabellar lines, marking a significant advancement in aesthetic medicine and expected to attract patients seeking non-long-term commitments.
- Clinical Research Support: The approval of Boey® is backed by two randomized, double-blind, placebo-controlled Phase 3 clinical trials involving 947 patients, showing that 60% and 65.7% of subjects achieved significant improvement in wrinkle severity by Day 7, demonstrating its efficacy.
- Market Demand: A survey by Allergan Aesthetics found that 80% of respondents are open to learning about new treatment options, and 79% wish they could temporarily preview treatment outcomes, indicating a growing market demand for short-term neurotoxin solutions that Boey® addresses.
- Future Plans: Allergan Aesthetics plans to begin training healthcare professionals on the use of Boey® in the coming months and is preparing for a commercial launch in multiple other countries, reflecting its strategic intent to expand in the global market.
See More
AbbVie and Enanta Gain EU Approval for Maviret Label Expansion
- Label Expansion Approval: AbbVie and Enanta's jointly developed hepatitis C therapy, Maviret, has received EU approval to be indicated for patients aged 3 and older with acute HCV infection, significantly broadening its market applicability.
- Significant Market Demand: Over 12 million individuals in Europe are infected with the hepatitis C virus, which can lead to severe complications such as cirrhosis and end-stage liver disease if untreated, highlighting the drug's potential and importance in addressing this public health issue.
- Clinical Trial Support: The approval is backed by results from late-stage trials demonstrating the efficacy of an eight-week regimen of Maviret, making it the only antiviral therapy available in the EU for both acute and chronic HCV infections, thereby enhancing its competitive edge.
- Strategic Implications: The label expansion of Maviret not only addresses the treatment needs of acute HCV patients but also lays the groundwork for AbbVie and Enanta's further expansion in the global market, strengthening their leadership position in the liver disease treatment sector.
See More
AbbVie’s MAVIRET Receives European Commission Approval for Hepatitis C Treatment
- Drug Approval: AbbVie's MAVIRET has received approval from the European Commission, becoming the only drug in the EU approved for treating both acute and chronic Hepatitis C, marking a significant expansion in the company's global market presence.
- Clinical Trial Success: In a Phase 3 trial involving 286 Hepatitis C patients, MAVIRET achieved a 96.2% sustained virological response at 12 weeks, demonstrating its efficacy and good safety profile, which enhances physician confidence in prescribing the drug.
- Market Potential: Given that Hepatitis C patients are at a significantly higher risk of developing cirrhosis and liver cancer if undiagnosed, the introduction of MAVIRET provides a new treatment option that addresses the urgent market demand for effective therapies.
- Stock Price Reaction: AbbVie's stock closed up 6.25% at $230.01 on Monday, with pre-market trading showing a further increase of 0.44% to $231.11, reflecting positive market sentiment regarding MAVIRET's approval and potentially boosting the company's future financial performance.
See More
